Beyond Meat, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 14, 2026, disclosing that the company effected a 1-for-30 reverse stock split of its common stock and a proportionate reduction in authorized shares, both becoming effective at 11:59 …
ACCO Brands Corporation filed an 8-K current report on August 14, 2026, disclosing that it has entered into a definitive agreement to acquire GXT Holding B.V., known as Trust, a pan-European provider of computer and gaming accessories, in a transaction valued at approximately $57 …
Digi Power X Inc. filed a current report on August 14, 2026, disclosing the release of its financial results for the fiscal second quarter ended June 30, 2026, along with a scheduled investor conference call on the same date.
Sotera Health Company filed a Form 8-K on August 14, 2026, disclosing that director James C. Neary resigned from the company's Board of Directors effective August 13, 2026.
The Western Union Company filed an 8-K on August 14, 2026, disclosing that on August 13, 2026, it entered into regulatory agreements with New York authorities related to its pending acquisition of International Money Express, Inc., while simultaneously receiving a suspension of approval from …
Standard Nuclear, Inc. filed a Form 8-K with the SEC on August 14, 2026, disclosing the appointment of Seth Cohen to its Board of Directors effective August 12, 2026, expanding the board from four to five members.
Delcath Systems, Inc. filed a Form 8-K on August 14, 2026, disclosing that its Board of Directors amended and restated the company's Bylaws effective August 12, 2026, adding exclusive forum provisions for certain legal claims.
Crinetics Pharmaceuticals, Inc. filed a Form 8-K on August 14, 2026, reporting that U.S. HSR Act antitrust waiting period expired on August 12, 2026, and that antitrust approvals in Austria, Germany, and Australia were received as of August 13, 2026, in connection with the …
Climb Bio, Inc. filed a current report on August 14, 2026, disclosing that its collaborator Beijing Mabworks Biotech Co., Ltd. announced the dosing of the first patient in a Phase 2 clinical trial in China for immunoglobulin A nephropathy on August 13, 2026.
Bitmine Immersion Technologies, Inc. filed a current report on Form 8-K on August 14, 2026, disclosing the declaration of cash dividends payable to holders of its 9.50% Series A Perpetual Preferred Stock, along with the applicable record and payment dates.